+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Bronchiolitis Obliterans Syndrome - Pipeline Insight, 2022

  • PDF Icon

    Clinical Trials

  • 96 Pages
  • November 2022
  • Region: Global
  • DelveInsight
  • ID: 5237630
This “Bronchiolitis Obliterans Syndrome - Pipeline Insight, 2022” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Bronchiolitis Obliterans Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Bronchiolitis Obliterans Syndrome Understanding

Bronchiolitis Obliterans Syndrome: Overview

Bronchiolitis obliterans syndrome (BOS) is a form of chronic lung allograft dysfunction that affects the majority of lung transplant recipients. It is the principal factor limiting long-term transplant survival. BOS is characterized by progressive airflow obstruction unexplained by acute rejection, infection, or other coexistent condition. Although BOS is a proven useful clinical syndrome that identifies patients at increased risk for death, its clinical course and underlying causative factors are now recognized to be increasingly heterogeneous. It is an uncommon respiratory disease characterized by fixed airway obstruction, where the bronchioles in the lung narrow down or get blocked by fibrous tissue. The disease is disabling and can be potentially severe. It may be caused occupationally by accidental, acute, high concentration exposure to industrial gases, such as nitrogen dioxide, etc. It manifests mainly by abnormal remodeling of the small airways (bronchioles), resulting in progressive airflow obstruction called Bronchiolitis Obliterans Syndrome (BOS).

"Bronchiolitis Obliterans Syndrome - Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Bronchiolitis Obliterans Syndrome pipeline landscape is provided which includes the disease overview and Bronchiolitis Obliterans Syndrome treatment guidelines. The assessment part of the report embraces, in depth Bronchiolitis Obliterans Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence in Bronchiolitis Obliterans Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve in Bronchiolitis Obliterans Syndrome.
This segment of the Bronchiolitis Obliterans Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Bronchiolitis Obliterans Syndrome Emerging Drugs

Liposomal Cyclosporine A: Zambon

Liposomal Cyclosporine A for Inhalation (LCsAi) is a novel liposomal formulation of cyclosporine A developed for inhaled delivery to the lungs. Calcineurin inhibitors (CNIs), like cyclosporine A, are highly potent immunosuppressive drugs and a cornerstone of lung transplant medicine. LCsAi is administered via a drug-specific Investigational eFlow Technology nebulizer system (PARI Pharma GmbH). The investigational drug-device combination is designed to deliver LCsAi to the site of disease in the lung. LCsAi has received orphan drug designation for the treatment of BOS from the US Food and Drug Administration and European Medicines Agency. Currently the drug, is being investigated in Phase III stage of Clinical trial evaluation for the treatment of Bronchiolitis Obliterans.

Bronchiolitis Obliterans Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Bronchiolitis Obliterans Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Bronchiolitis Obliterans Syndrome

There are approx. 5+ key companies which are developing the therapies for Bronchiolitis Obliterans Syndrome. The companies which have their Bronchiolitis Obliterans Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Zambon.

Phases

The report covers around 5+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Bronchiolitis Obliterans Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical
Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Bronchiolitis Obliterans Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bronchiolitis Obliterans Syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bronchiolitis Obliterans Syndrome drugs.

Bronchiolitis Obliterans Syndrome Report Insights

  • Bronchiolitis Obliterans Syndrome Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Bronchiolitis Obliterans Syndrome Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Bronchiolitis Obliterans Syndrome drugs?
  • How many Bronchiolitis Obliterans Syndrome drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bronchiolitis Obliterans Syndrome?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Bronchiolitis Obliterans Syndrome?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Bronchiolitis Obliterans Syndrome and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Zambon
  • Genentech
  • Incyte Corporation
  • Mereo BioPharma
  • Incyte Corporation

Key Products

  • Liposomal Cyclosporine A
  • Pirfenidone
  • Ruxolitinib
  • Alvelestat
  • Itacitinib


This product will be delivered within 1-3 business days.

Table of Contents

Introduction

Executive Summary

Bronchiolitis Obliterans Syndrome : Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Bronchiolitis Obliterans Syndrome - Analytical Perspective

Late Stage Products (Phase III)
  • Comparative Analysis
Liposomal Cyclosporine A: Zambon
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
Ruxolitinib: Incyte Corporation
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I/II)
  • Comparative Analysis
Alvelestat: Mereo BioPharma
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I)
  • Comparative Analysis
LAM-001: AI Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
Preclinical and Discovery Stage Products
  • Comparative Analysis
Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Bronchiolitis Obliterans Syndrome Key Companies

Bronchiolitis Obliterans Syndrome Key Products

Bronchiolitis Obliterans Syndrome -Unmet Needs

Bronchiolitis Obliterans Syndrome -Market Drivers and Barriers

Bronchiolitis Obliterans Syndrome -Future Perspectives and Conclusion

Bronchiolitis Obliterans Syndrome Analyst Views

Bronchiolitis Obliterans Syndrome Key Companies

Appendix

List of Tables
Table 1 Total Products for Bronchiolitis Obliterans Syndrome
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Bronchiolitis Obliterans Syndrome
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Zambon
  • Genentech
  • Incyte Corporation
  • Mereo BioPharma
  • Incyte Corporation